fda drug safety communication semaglutide naion 2025 Novo Nordisk's Wegovy® pill (oral 25 mg, once daily) has just been approved by the US as the first oral GLP‑1 receptor agonist for long‑term weight management and CV risk Nestlé's GLP-1 strategy reframes dietary:gluten-free Size:Semaglutide 1mg

fda drug safety communication semaglutide naion 2025 Novo Nordisk's Wegovy® pill (oral 25 mg, once daily) has just been approved by the US as the first oral GLP‑1 receptor agonist for long‑term weight management and CV risk Nestlé's GLP-1 strategy reframes dietary:gluten-free Size:Semaglutide 1mg

Nestlé's GLP-1 strategy reframes food formulation around nutrient density

This might include switching to another GLP-1 receptor agonist, adding or adjusting other oral hypoglycaemic agents, or considering injectable therapies such as insulin if appropriate, in line with NICE guidance (NG28)

dietary:gluten-free

Size:Semaglutide 1mg

CVOTs In response to FDA guidelines requiring the assessment of anti-diabetic therapeutics in relation to cardiovascular risk, several CVOTs have been performed